JPX and LINC00641 ncRNAs expression in prostate tissue: a case-control study

BACKGROUND AND PURPOSE: Prostate cancer (PC) is the second most prevalent cancer in men. Prostate-specific antigen (PSA) is the main biomarker for screening PC. An increase in PSA could lead to false-positive results. Thus, more appropriate markers should be investigated. In the present study, JPX a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sajjadi, Roshanak S., Modarressi, Mohammad Hossein, Tabatabaiefar, Mohammad Amin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8407155/
https://www.ncbi.nlm.nih.gov/pubmed/34522197
http://dx.doi.org/10.4103/1735-5362.323916
Descripción
Sumario:BACKGROUND AND PURPOSE: Prostate cancer (PC) is the second most prevalent cancer in men. Prostate-specific antigen (PSA) is the main biomarker for screening PC. An increase in PSA could lead to false-positive results. Thus, more appropriate markers should be investigated. In the present study, JPX and LINC00641 expression levels were measured in tumoral prostate tissue compared with the non-tumor tissue. EXPERIMENTAL APPROACH: 43 pairs of prostate tumoral and non-tumor tissue were prepared. The expression levels of JPX and LINC00641 were investigated by RT-qPCR. FINDINGS/RESULTS: Significant upregulation of LINC00641 (2.47 ± 0.5 vs 1.41 ± 0.2) and downregulation of JPX (1.42 ± 0.6 vs 2.83 ± 1.0) were observed in PC tissues compared with the normal tissues (their adjacent non-tumoral tissues). CONCLUSION AND IMPLICATIONS: Dysregulation of JPX and LINC00641 in PC patients could be used in the future as a prognostic biomarker in PC.

Ejemplares similares